Format

Send to

Choose Destination
RMD Open. 2015 Dec 30;1(1):e000181. doi: 10.1136/rmdopen-2015-000181. eCollection 2015.

Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry.

Author information

1
Department of Rheumatology , Swedish Medical Center and University of Washington , Seattle, Washington , USA.
2
Inflammation Global Development , Amgen Inc. , Thousand Oaks, California , USA.
3
Epidemiology and Outcomes Research, Corrona, LLC , Southborough, Massachusetts , USA.
4
Department of Biostatistics , Axio Research LLC , Seattle, Washington , USA.
5
Center for Rheumatology, Albany Medical College and the Center for Rheumatology , Albany, New York , USA.
6
Epidemiology and Outcomes Research, Corrona, LLC, Southborough, Massachusetts, USA; Division of Rheumatology, New York University School of Medicine, New York, New York, USA.

Abstract

OBJECTIVES:

To characterise the comparative effectiveness of combination therapy (a tumour necrosis factor inhibitor (TNFi) and a conventional synthetic disease-modifying antirheumatic drug (csDMARD) such as methotrexate) and monotherapy (TNFi only) for psoriatic arthritis (PsA) from a large US registry.

METHODS:

The analysis included adult patients with PsA who were enrolled in the Corrona database (ClinicalTrials.gov, NCT01402661), had initiated a TNFi, were biologic naïve, and had a follow-up visit ≥90 days after drug initiation. The endpoints of the analysis were TNFi persistence (drug survival) and time to Clinical Disease Activity Index (CDAI) remission. All analyses were performed using propensity scoring, which were estimated using CDAI and patient sex, to control for channelling bias.

RESULTS:

Of 519 patients meeting the inclusion criteria (318 with combination therapy and 201 with monotherapy), the analysis population was 497 for TNFi persistence and 380 for time to remission. The difference between combination therapy (TNFi+methotrexate, 91% of patients; TNFi+other csDMARD, 9%) and monotherapy was not statistically significant for TNFi persistence (32 and 31 months, p=0.73) and time to remission (21 and 25 months, p=0.56). Predictors of TNFi persistence included Hispanic ethnicity (longer persistence), PsA duration (longer persistence), history of methotrexate use (shorter persistence), body mass index (shorter persistence) and disease activity (shorter persistence).

CONCLUSIONS:

Patients with PsA from a large US registry experienced similar TNFi persistence on combination therapy and monotherapy. Prospective, randomised clinical trials evaluating the efficacy of combination therapy versus monotherapy would provide much-needed clarity on treatment options for patients with PsA.

TRIAL REGISTRATION NUMBER:

NCT01402661.

KEYWORDS:

Anti-TNF; DMARDs (biologic); Psoriatic Arthritis

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center